1. Leukemia. 2016 Jun;30(6):1418-21. doi: 10.1038/leu.2015.318. Epub 2015 Nov 19.

Extreme mutational selectivity of axitinib limits its potential use as a 
targeted therapeutic for BCR-ABL1-positive leukemia.

Zabriskie MS(1), Eide CA(2)(3), Yan D(1), Vellore NA(1), Pomicter AD(1), Savage 
SL(2), Druker BJ(2)(3), Deininger MW(1)(4), O'Hare T(1)(4).

Author information:
(1)Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
(2)Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 
USA.
(3)Howard Hughes Medical Institute, Portland, OR, USA.
(4)Division of Hematology and Hematologic Malignancies, University of Utah, Salt 
Lake City, UT, USA.

DOI: 10.1038/leu.2015.318
PMCID: PMC4873472
PMID: 26582647 [Indexed for MEDLINE]